Table 1.
Characteristics of Study Subjects by Recipient C2 Ligand Status
| Variable | C2 Negative N (%) | C2 Positive N (%) | p-value |
|---|---|---|---|
| Number of Patients | 368 | 541 | |
| Number of centers | 82 | 86 | |
| Age, median (range), years | 56 (20–74) | 57 (20–74) | 0.54 |
| Age at transplant | 0.13 | ||
| 20–29 | 13 ( 4) | 32 ( 6) | |
| 30–39 | 32 ( 9) | 31 ( 6) | |
| 40–49 | 63 (17) | 86 (16) | |
| 50+ | 260 (71) | 392 (72) | |
| Recipient race/ethnicity | 0.15 | ||
| Caucasian race, non-Hispanic | 336 (95) | 492 (93) | |
| African American race, non-Hispanic | 3 ( 1) | 17 ( 3) | |
| Asian race, non-Hispanic | 1 (<1) | 3 ( 1) | |
| Native American race, non-Hispanic | 0 | 1 (<1) | |
| Hispanic, Caucasian race | 13 ( 4) | 16 ( 3) | |
| Other/Multiple | 1 (<1) | 0 | |
| Missing | 14 | 12 | |
| Male Sex | 214 (58) | 305 (56) | 0.60 |
| Karnofsky score prior to transplant | |||
| < 90 | 129 (35) | 173 (32) | 0.38 |
| >= 90 | 196 (53) | 313 (58) | |
| Missing | 43 (12) | 55 (10) | |
| HLA matching | 0.25 | ||
| 8-Aug | 294 (80) | 418(77) | |
| 7/8 MM at HLA-A | 23 ( 6) | 39 ( 7) | |
| 7/8 MM at HLA-B | 8 ( 2) | 26 ( 5) | |
| 7/8 MM at HLA-C | 41 (11) | 53 (10) | |
| 7/8 MM at HLA-DRB1 | 2 ( 1) | 5 ( 1) | |
| Disease at transplant | 0.86 | ||
| AML | 249 (68) | 363 (67) | |
| MDS | 119 (32) | 178 (33) | |
| ATG Use - Yes | 116 (32) | 201 (37) | 0.08 |
| Alemtuzumab Use - Yes | 26 ( 7) | 47 ( 9) | 0.40 |
| Disease status at transplant | 0.49 | ||
| Early | 160 (43) | 217 (40) | |
| Intermediate | 57 (15) | 77 (14) | |
| Advanced | 125 (34) | 197 (36) | |
| Missing | 26 ( 7) | 50 ( 9) | |
| Conditioning regimen | 0.60 | ||
| TBI 200 cGy | 7 ( 2) | 4 ( 1) | |
| Fludarabine + TBI | 72 (20) | 98 (18) | |
| Fludarabine + Cy | 32 ( 9) | 51 ( 9) | |
| Fludarabine + Melphalan | 100 (27) | 139 (26) | |
| Fludarabine + Busulfan + ATG | 112 (30) | 195 (36) | |
| Fludarabine + Busulfan (No ATG) | 41 (12) | 49 ( 9) | |
| Thiotepa + Cy + ATG | 4 ( 1) | 5 ( 1) | |
| GvHD prophylaxis | 0.94 | ||
| CsA + MTX | 16 ( 4) | 25 ( 5) | |
| CsA + MMF | 63 (17) | 96 (18) | |
| CsA ± other (No MTX and no MMF) | 13 ( 4) | 13 ( 2) | |
| FK506 + MTX | 121 (33) | 177 (33) | |
| FK506 + MMF | 92 (25) | 139 (26) | |
| FK506 ± other (No MTX and no MMF) | 25 ( 7) | 45 ( 9) | |
| T-cell depletion | 38 (10) | 46 ( 9) | |
| Stem cell source | 0.78 | ||
| Bone marrow | 70 (19) | 99 (18) | |
| Peripheral Blood Progenitor Cells | 298 (81) | 442 (82) | |
| Donor/recipient sex match | 0.10 | ||
| Male -> Male | 165 (45) | 214 (40) | |
| Male -> Female | 99 (27) | 131 (24) | |
| Female -> Male | 48 (13) | 91 (17) | |
| Female -> Female | 56 (15) | 105 (19) | |
| Donor/recipient CMV match | 0.14 | ||
| Negative/Negative | 91 (25) | 150 (28) | |
| Negative/Positive | 156 (42) | 184 (34) | |
| Positive/Negative | 37 (10) | 57 (11) | |
| Positive/Positive | 77 (21) | 136 (25) | |
| Unknown | 7 ( 2) | 14 ( 3) | |
| TBI Use - Yes | 92 (25) | 118 (22) | 0.26 |
| Donor age, median (range), years | 34 (18–59) | 35 (18–61) | 0.20 |
| Donor age | 0.32 | ||
| 18–19 | 9 ( 2) | 9 ( 2) | |
| 20–29 | 112 (30) | 158 (29) | |
| 30–39 | 136 (37) | 197 (36) | |
| 40–49 | 91 (25) | 128 (24) | |
| 50+ | 20 ( 5) | 49 ( 9) | |
| Interval from Dx to Tx, months, AML, Median, Range | 6 (1.0–90) | 7 (0.5–69) | 0.22 |
| Interval from Dx to Tx, months, MDS, Median, Range | 10 (0.6–186) | 10 (1–270) | 0.44 |
| Year of transplant | 0.15 | ||
| 1999 | 4 ( 1) | 4 ( 1) | |
| 2000 | 14 ( 4) | 11 ( 2) | |
| 2001 | 28 ( 8) | 27 ( 5) | |
| 2002 | 17 ( 5) | 33 ( 6) | |
| 2003 | 36 (10) | 50 ( 9) | |
| 2004 | 64 (17) | 70 (13) | |
| 2005 | 70 (19) | 116 (21) | |
| 2006 | 92 (25) | 150 (28) | |
| 2007 | 43 (12) | 80 (15) | |
| Median follow-up of survivors, months | 63 (5–133) | 58 (4–121) | 0.009a |
Abbreviations: Dx – Diagnosis, Tx - Transplant
a
– Log-rank p-value.